Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.61 |
| ▸ | CTSL | P07711 | 6/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18353012 | 0.95 | CTRB1 (0.67) | CTRB1CTSLTRPM8ALDH1A1ALOX15 | |
| SCHEMBL18352491 | 0.95 | CTRB1 (0.67) | CTRB1CTSLTRPM8ALDH1A1ALOX15 | |
| SCHEMBL18355339 | 0.90 | CTRB1 (0.57) | CTRB1CTSLTRPM8ALDH1A1ALOX15 | |
| SCHEMBL18352674 | 0.89 | CTRB1 (0.50) | CTRB1CTSLALDH1A1HCAR2CYP3A4 | |
| SCHEMBL18352495 | 0.89 | CTRB1 (0.50) | CTRB1CTSLALDH1A1HCAR2CYP3A4 | |
| SCHEMBL18355136 | 0.87 | CTSL (0.44) | CTRB1CTSLALDH1A1CTSKCTSB | |
| SCHEMBL18355337 | 0.87 | CYP1A2 (0.53) | CTRB1CTSLHCAR2 | |
| SCHEMBL18364335 | 0.86 | CTSL (0.48) | CTRB1CTSLHCAR2 | |
| SCHEMBL18364431 | 0.86 | CTSL (0.48) | CTRB1CTSLHCAR2 | |
| SCHEMBL18352599 | 0.86 | CTRB1 (0.51) | CTRB1CTSLCTSBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | CTRB1 2782/4885CTSL 2900/4885TRPM8 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.